fbpx

Locoregional Stomach Cancer

Gastric Pyloric Adenocarcinoma

Male, 39 years

Patient Internal ID: 266349119

ICD-10 code

C16.3 Malignant Neoplasm of Pyloric Antrum

Diagnosis (Incl. Metastases/Stage) and Year

February 2019
Gastric Pyloric Adenocarcinoma cT3NXM0 (pT3pN2M0 G3 (pLVI0)) stage III.

Previous Treatment

Surgery, Chemotherapy (FLOT scheme).

Prognosis and Survival Expectation

The prognosis remains poor, the median overall survival for Locoregional Gastric Cancer is about 43 months. The 5-year relative survival rates for Locoregional Stomach Cancer are 35%.

Treatment Provided

Autologous DCV (10 doses) and CIK (4 doses) over a period of 14 months. Additionally, the patient received Xenogeneic Preventive and Therapeutic Anti-Cancer Vaccine (PTAC) (10 vaccines).

Patient Survival/Condition and Year
Date of Review: 02/12/2023

The patient has survived for 47 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Surgery and Chemotherapy, has extended patient survival by an estimate of around 5 months so far. The patient has no signs of disease recurrence.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.